Aura Biosciences Releases Data Presentation Of Eye Cancer Candidate

  • Aura Biosciences Inc AURA announced the presentation of interim Phase 2 safety and efficacy data of belzupacap sarotalocan (bel-sar; AU-011) with 9-10 months of follow-up.
  • The trial evaluates two clinical endpoints: tumor control and visual acuity preservation using the suprachoroidal (SC) route of administration for early-stage choroidal melanoma (indeterminate lesions and small choroidal melanoma (IL/CM)). 
  • The results showed a statistically significant reduction in the tumor growth rate (-0.289 mm/yr, p = <0.0001) compared to each patient's documented growth rate at study entry and a 100% (8/8) tumor control rate. 
  • Related: Aura Biosciences Details Interim Data From Mid-Stage Study Of Ocular Oncology Drug.
  • In addition, the visual acuity preservation rate was 88% (7/8), with most patients at risk for vision loss with tumors close to the fovea or optic disk. 
  • The overall tolerability profile of bel-sar was generally favorable, with no dose-limiting toxicities, treatment-related SAEs, or significant AEs reported.
  • There was no posterior inflammation and only mild anterior inflammation (Grade 1) in 20% of the patients. Treatment-related AEs were predominantly mild and resolved without sequalae. 
  • Price Action: AURA shares are down 2.42% at $10.88 on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareSmall CapGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!